Dietary guidelines-based eating plan to reduce menopausal symptoms in overweight and obese women
Official title: Effects of a Dietary Intervention Based on the Dietary Guidelines for the Brazilian Population on the Reduction of Menopausal Symptoms in Overweight and Obese Women
Run by Federal University of Health Science of Porto Alegre · NCT07822230 · Data updated 2026-11-12
A randomized trial will test whether following healthy eating guidance from Brazil’s dietary guidelines can lessen menopausal symptoms in women who are overweight or obese.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 65 Years |
| Sex | Women only |
| Enrollment | 74 (estimated) |
| Sponsor | Federal University of Health Science of Porto Alegre Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Porto Alegre, Rio Grande do Sul) |
| Status | Recruiting |
| Started | May 6, 2026 |
| Main results expected | July 30, 2027 |
| Study ends | July 30, 2027 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT07822230 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 40–65 who are perimenopausal or postmenopausal, have BMI ≥ 25 kg/m², and have access to the internet.
✕Probably not a fit
Individuals with conditions requiring hormone therapy or ongoing obesity medications, or those unable to follow dietary guidance, may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized clinical trial evaluates the impact of a dietary intervention based on the Dietary Guidelines for the Brazilian Population (GAPB) on menopausal symptoms in women aged 40–65 who are perimenopausal or postmenopausal and overweight or obese. Participants will receive printed nutrition guidance and attend five in-person or virtual sessions, with some materials provided in printed form only. The study aims to determine if adopting these dietary guidelines can reduce vasomotor symptoms, sleep disturbances, mood changes, and related complaints associated with menopause. Enrollment requires internet access and informed consent, with exclusions including pregnancy, current hormone therapy, or treatments for obesity. The trial is led by the Federal University of Health Science of Porto Alegre, with collaboration from a local hospital group, and is based in Porto Alegre, Brazil.
Why it matters
Potential benefit: If successful, participants may experience reduced menopausal symptoms and improved quality of life through healthier eating patterns.
How similar studies have gone: Previous work suggests dietary patterns can influence menopausal symptoms, though this specific GAPB-based approach is novel in this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 40 to 65 years * In the perimenopausal or postmenopausal stage (based on clinical criteria and/or self-report) * Exhibiting clinical symptoms characteristic of menopause * Diagnosed as overweight or obese (BMI ≥ 25 kg/m²) * Internet access via mobile phone or computer * Agreeing to participate by signing the Informed Consent Form (ICF) Exclusion Criteria: * Pregnancy * Undergoing hormone replacement therapy * Taking medications for obesity * Diagnosed with active neoplasms undergoing chemotherapy or immunosuppressive treatment * Cognitive impairment
Where it's running
-
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil Recruiting
Study contacts
- Principal investigator: Fernanda M Busnello, PhD — Federal University of Health Science of Porto Alegre
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Haelan 951 for menopause symptoms in peri- and postmenopausal women
This open-label study tests daily Haelan 951, a fermented soy product, to see if it helps with hot flashes, sleep, and quality of life in peri- and postmenopausal women.
-
Improving midlife women's health during the menopausal transition
This study will test whether medicines (metformin, semaglutide, blood pressure and cholesterol drugs) combined with lifestyle changes can reduce bothersome menopausal symptoms and lower future heart and metabolic disease risk in women aged 45–55 who are in the late menopausal transition.
-
Hop extract vs soy isoflavone for menopausal symptoms
This study tests whether a full-spectrum hop extract helps reduce menopausal mood symptoms better than soy isoflavones in peri- and postmenopausal women.
-
Lifestyle changes to ease menopausal symptoms, sleep problems, and anxiety
Researchers are testing whether a structured lifestyle education program helps perimenopausal and postmenopausal women see fewer menopausal symptoms, better sleep, and less anxiety compared to usual care.
-
Virtual registry for menopause and perimenopause in Australia
This study is creating an online registry to collect information from Australian women about their experiences with menopause and perimenopause to help improve healthcare and support for them.
-
Impact of Duavive on mood and anxiety in menopausal women
This study is testing if a new hormone treatment can help improve mood and reduce anxiety in women going through menopause.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.